Brainsway (NASDAQ:BWAY) Announces Quarterly Earnings Results, Beats Estimates By $0.07 EPS

Brainsway (NASDAQ:BWAY) issued its earnings results on Wednesday. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.07, Zacks reports. Brainsway had a net margin of 15.68% and a return on equity of 12.51%. The company had revenue of $15.53 million during the quarter, compared to the consensus estimate of $14.63 million.

Here are the key takeaways from Brainsway’s conference call:

• BrainsWay delivered strong Q1 2026 results, with revenue up 35% year over year to $15.5 million, net income more than doubling to $2.3 million, and adjusted EBITDA rising 119% to $2.8 million.
• The company reported its 11th consecutive quarter of profitability, supported by expanding margins, disciplined cost control, and a recurring revenue model that continues to gain traction.
• Demand indicators improved, including 117 Deep TMS systems shipped in the quarter, a total install base of about 1,820 systems, and remaining performance obligations rising to $75 million, with most new contracts being multi-year agreements.
• Management highlighted reimbursement and adoption progress for both Deep TMS and the SWIFT protocol, including expanded payer coverage, growing interest from providers, and expectations for $40 million-$50 million of SWIFT-covered lives by year-end.
• The company remains focused on pipeline and strategic expansion, including an upcoming FDA filing for PTSD symptoms in MDD, ongoing alcohol use disorder trials, and additional minority investments in mental health networks and Neurolief’s ProlivRx platform.

Brainsway Price Performance

Shares of NASDAQ BWAY traded down $1.29 during mid-day trading on Friday, hitting $15.03. 260,654 shares of the company’s stock traded hands, compared to its average volume of 191,947. The company’s 50-day moving average is $14.52 and its two-hundred day moving average is $11.62. The company has a market capitalization of $601.80 million, a P/E ratio of 42.94 and a beta of 1.23. Brainsway has a 1 year low of $4.94 and a 1 year high of $17.35.

Institutional Trading of Brainsway

Several hedge funds have recently made changes to their positions in BWAY. ARK Investment Management LLC purchased a new stake in shares of Brainsway during the 4th quarter valued at about $2,422,000. UBS Group AG grew its stake in shares of Brainsway by 2,028.6% during the third quarter. UBS Group AG now owns 63,878 shares of the company’s stock valued at $963,000 after buying an additional 60,877 shares during the last quarter. Two Sigma Investments LP grew its stake in shares of Brainsway by 25.2% during the third quarter. Two Sigma Investments LP now owns 102,902 shares of the company’s stock valued at $1,551,000 after buying an additional 20,706 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Brainsway by 69.6% in the third quarter. Millennium Management LLC now owns 39,841 shares of the company’s stock worth $600,000 after buying an additional 16,354 shares during the period. Finally, Trexquant Investment LP purchased a new stake in shares of Brainsway in the fourth quarter worth approximately $245,000. 30.11% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have commented on the stock. Northland Securities set a $15.00 price objective on shares of Brainsway in a report on Thursday, January 22nd. Wall Street Zen raised shares of Brainsway from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. HC Wainwright dropped their price objective on shares of Brainsway from $30.00 to $15.00 and set a “buy” rating for the company in a report on Thursday, March 12th. Zacks Research downgraded shares of Brainsway from a “strong-buy” rating to a “hold” rating in a report on Monday. Finally, Weiss Ratings raised shares of Brainsway from a “hold (c)” rating to a “buy (b-)” rating in a report on Friday, April 24th. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

About Brainsway

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.